bluuebunny/crossref_metadata_2025_split huggingface dataset:
lncRNA-Associated ceRNA Networks in Spleen of Nocth1-correlated T-ALL Leukemia Mice
Authors: Shi Min , Wang Shaohua , Li Xiaofei , Li Yongjun 
Published: January 2020

Abstract
Background Acute T-lymphocytic leukemia (T-ALL) is a highly aggressive malignant tumor in leukemia. Nocth1 is considered as an major oncogene in the development of T-ALL. Increasing evidences have revealed that the occurrence and progression of T-ALL referred to abnormal gene expression, pathway activation and the regulation between these genes. However, the potential lncRNA-associated competing endogenous RNA (ceRNA) network involved in spleen of Nocth1-correlated T-ALL leukemia mice remains unclear. Methods Overexpression of Notch intracellular domain (ICN) of Notch1 by retroviral infection was used to set up mouse T-ALL model. Deep RNA-sequencing analysis was performed the expression of lncRNAs and mRNA in spleen of T-ALL mice and C57BL/6 mice. Results The deep RNA-sequencing analysis shown that 1833 lncRNAs and 4626 mRNAs were deregulated according to the P-value (p<0.05) and fold change (>2-fold) in spleen of T-ALL leukemia mice compared with that of C57BL/6 mice. Gene Ontology(GO) and KEGG pathway analysis were performed to reveal the potential roles of differentiated expressed lncRNAs. Co-expression Network was performed to reveal the regulation relationship between the differentiated expressed lncRNAs and mRNAs. CeRNA prediction constructed the lncRNA-miRNA-mRNA model to find the core ceRNA based on regression model analysis and seed sequence matching methods. Conclusion This study provided a systematic overview of the altered lncRNAs and mRNA expression, pathway and ceRNA regulation network in the pathogenesis of Nocth1-correlated T-ALL.
One-year Serial Measurements of High-sensitivity Troponin T in Hemodialysis Patients A Randomized Placebo-controlled Sub-study Investigating Angiotensin-II-Blockade, Variation Over Time and Associations with Clinical Outcome
Authors: Peters Christian Daugaard , Kjaergaard Krista D. , Christensen Kent L. , Bibby Bo Martin , Jespersen Bente , Jensen Jens Dam 
Published: January 2020

Abstract
Background Troponin T (TnT) is a well-known risk factor for negative outcome in hemodialysis (HD) patients, but little is known about variation over time, and the impact of clinical and dialysis specific factors. This study investigated the effect of angiotensin II receptor blockade (ARB), short and long-term variation in TnT and associations with clinical parameters.Methods In this analysis based on the SAFIR-cohort (Clinical Trials ID: NCT00791830) 81 HD patients were randomized double-blind for placebo (n=40) or angiotensin II receptor blocker (ARB) treatment (n=41) with irbesartan (150-300 mg) and followed for 12 months with six serial measurements of TnT using a high-sensitivity assay. Results Fifty-four patients (67%) completed follow-up. Baseline TnT-medians (min-max) were (placebo/ARB): 45(14-295)/46(10-343)ng/L. ARB-treatment did not significantly affect mean TnT-levels over the 12-month study period. Median week-to-week and one-year TnT-variation (5th-95th-percentile range) using all samples regardless of intervention were: 0(-14-10)ng/L (week-to-week) and 3(-40-71)ng/L (12 months). Median TnT-amplitude, capturing the change from the lowest to the highest TnT-value observed during the one-year study period was 38% or 20.5 ng/L. Median ratios with 95% limits of agreement were: 1.00(0.73-1.37); P=0.92 (1 week/baseline; n=77) and 1.07(0.52-2.25); P=0.19 (12 months/baseline; n=54). Baseline TnT was positively correlated with diabetes, ultrafiltration volume, arterial stiffness, change in intradialytic total peripheral resistance and N-terminal pro b-type natriuretic peptide (NT-proBNP) and negatively correlated with hematocrit, residual renal function and change in intradialytic cardiac output. High baseline TnT was associated with a higher risk of admission and cardiovascular (CV) events during follow-up. Increase in TnT over time (ΔTnT=12-months-baseline) was significantly associated with increase in left ventricular (LV) mass and NT-proBNP and decrease in LV ejection fraction and late intradialytic stroke volume. ΔTnT was not significantly associated with admissions, CV or intradialytic hypotensive events during follow-up. Admissions were significantly more likely with a high (TnT-amplitude>20.5 ng/L) than a low TnT-amplitude. Peaks in TnT were less frequent in aspirin-treated patients. Conclusion ARB-treatment had no significant effect on TnT-levels. Week-to-week variation was generally low, yet over 12 months individual patients had considerable TnT fluctuations. Rise in TnT over time was significantly correlated with markers of cardiac deterioration.
Immune dysfunction in ankylosing spondylitis (AS) and the potential of tumor necrosis factor-α (TNF-α) inhibitor Anbainuo as an effective treatment
Authors: Yang Mingcan , Lv Qing , Wei Qiujing , Jiang Yutong , Qi Jun , Xiao Min , Fang Linkai , Xie Ya , Cao Shuangyan , Lin Zhiming , Zhang Yanli , Tu Liudan , Zhao Minjing , Pan Yunfeng , Jin Ou , Gu Jieruo 
Published: January 2020

Abstract
Background Studies into ankylosing spondylitis (AS) and its relationship with immune function are controversial, and the correlation between the efficacy of TNF-α inhibitor and changes in immune function is unclear. Methods A total of 40 immune cells were tested with flow cytometry, and the results of 105 HC (healthy control) subjects, 177 active-stage AS patients, and 23 AS cases before and after 12 weeks of Anbainuo therapy were analyzed. Results Compared with the HC group, the proportion of immune cells, such as naïve and central memory CD4+T cells, in AS increased (p<0.0001), but effector memory and terminally differentiated CD4+T cells were decreased (p<0.01 and 0.0001, respectively). Naïve, central memory, and effector memory CD8+T cells were increased (p<0.0001, 0.001, and 0.01, respectively), but terminally differentiated CD8+T cells were decreased (p<0.0001). Th1 cells (helper T cells-1), Tfh1 cells (follicular helper T cells-1), Tc1 cells (cytotoxic T cells-1), and Tregs (regulatory T cells) were lower (p<0.01, 0.05, 0.0001, and 0.001, respectively), but Th17 cells, Tfh17 cells, and Tc cells were higher (p<0.001, 0.0001 and 0.001, respectively). The proportions of total B cells and class-switched B cells were increased (p<0.05), but non-switched B cells, plasma cells, memory B cells, and immature Bregs (regulatory B cells) were lower (p<0.01, 0.0001, 0.0001, and 0.0001, respectively). After Anbainuo therapy, the percentage of Tregs and B10 cells (IL-10-producing regulatory B cells) had increased (p<0.01and 0.05, respectively), and the increase in Tregs was positively correlated with the decrease in CRP (C-reactive protein) (r= 0.489, p=0.018). Conclusions We found that, in terms of both innate and acquired immunity, active-stage AS patients have an immunity imbalance involving multiple types of immune cells, including CD4+T cells, CD8+T cells, Th cells, Tfh cells, Tc cells, Tregs, Bregs, and B cells. Anbainuo can not only help to inhibit disease activity and partial immune function imbalance in AS but can also increase the number of negative regulatory cells in inflammation.
Physical Activity Reduces Anxiety And Regulates Brain Fatty Acid Synthesis
Authors: Liśkiewicz Arkadiusz Damian , Przybyła Marta , Wojakowska Anna , Marczak Łukasz , Bogus Katarzyna , Nowacka-Chmielewska Marta , Liśkiewicz Daniela , Małecki Andrzej , Barski Jarosław , Lewin-Kowalik Joanna , Toborek Michal 
Published: January 2020

Abstract
Physical activity impacts brain functions, but the direct mechanisms of this effect are not fully recognized or understood. Among multidimensional changes induced by physical activity, brain fatty acids (FA) appear to play an important role; however, the knowledge in this area is particularly scarce. Here we performed global metabolomics profiling of the hippocampus and the frontal cortex (FC) in a model of voluntary running in mice. Examined brain structures responded differentially to physical activity. Specifically, the markers of the tricarboxylic acid (TCA) cycle were downregulated in the FC, whereas glycolysis was enhanced in the hippocampus. Physical activity stimulated production of myristic, palmitic and stearic FA; i.e., the primary end products of de novo lipogenesis in the brain, which was accompanied by increased expression of hippocampal fatty acid synthase (FAS), suggesting stimulation of lipid synthesis. The changes in the brain fatty acid profile were associated with reduced anxiety level in the running mice. Overall, the study examines exercise-related metabolic changes in the brain and links them to behavioral outcomes.
Myelination- and immune mediated MR-based brain network correlates
Authors: Cerina Manuela , Muthuraman Muthuraman , Gallus Martin , Koirala Nabin , Dik Andre , Wachsmuth Lydia , Hundehege Petra , Schiffler Patrick , Tenberge Jan-Gerd , Fleischer Vinzenz , Gonzalez-Escamilla Gabriel , Narayanan Venu , Krämer Julia , Faber Cornelius , Budde Thomas , Groppa Sergiu , Meuth Sven G 
Published: January 2020

Abstract
Background:
Multiple sclerosis (MS) is an autoimmune disease of the central nervous system (CNS), characterized by inflammatory and neurodegenerative processes. Despite demyelination being a hallmark of the disease, how it relates to neurodegeneration has still not been completely unraveled, and research is still ongoing into how these processes can be tracked non-invasively. Magnetic resonance imaging (MRI) derived brain network characteristics, which closely mirror disease processes and relate to functional impairment, recently became important variables for characterizing immune-mediated neurodegeneration, however their histopathological basis remains unclear.
Methods:
In order to determine the MRI-derived correlates of myelin dynamics and to test if brain network characteristics derived from diffusion tensor imaging reflect microstructural tissue reorganization, we took advantage of the cuprizone model of general demyelination in mice and performed longitudinal histological and imaging analyses with behavioral tests. By introducing cuprizone into the diet, we induced targeted and consistent demyelination of oligodendrocytes, over a period of 5 weeks. Subsequent myelin synthesis was enabled by reintroduction of normal food.
Results:
Using specific immune-histological markers, we demonstrated that two weeks of cuprizone diet induced a 52% reduction of myelin content in the corpus callosum (CC) and a 35% reduction in the neocortex. An extended cuprizone diet increased myelin loss in the CC, while remyelination commenced in the neocortex. These histologically determined dynamics were reflected by MRI measurements from diffusion tensor imaging. Demyelination was associated with decreased fractional anisotropy (FA) values and increased modularity and clustering at the network level. MRI-derived modularization of the brain network and FA reduction in key anatomical regions, including the hippocampus, thalamus and analyzed cortical areas, were closely related to impaired memory function and anxiety-like behavior.
Conclusion:
Network specific remyelination, shown by histology and MRI metrics, determined amelioration of functional performance and neuropsychiatric symptoms. Taken together, we illustrate the histological basis for the MRI-driven network responses to demyelination, where increased modularity leads to evolving damage and abnormal behavior in MS. Quantitative information about in vivo myelination processes is mirrored by diffusion based imaging of microstructural integrity and network characteristics.
Catch-up Growth in Intrauterine Growth-restricted Piglets Associated with the Return of Pancreatic and Intestinal Functions via Porcine Glucagon-like peptide-2 Microspheres
Authors: Qi Ke-ke , Wu Jie , Zhou Wen-Jun , Deng Bo , Men Xiao-ming , Xu Zi wei 
Published: January 2020

Abstract
Background Intrauterine growth restriction (IUGR) results in abnormal morphology and gastrointestinal function. As a gastrointestinal growth factor, the manner by which the porcine glucagon-like peptide-2 (pGLP-2) microsphere administration catches up with the growth of IUGR piglets was investigated. Methods Fourteen newborn IUGR piglets were assigned into the IUGR and pGLP-2 microsphere groups. The piglets in the pGLP-2 microsphere group were intraperitoneally administered with 100 mg of pGLP-2 microspheres on day 1 of birth. Results From days 15 to 26 of trial, the body weight of the IUGR piglets treated with pGLP-2 microspheres was significantly higher than that in the control group. Importantly, the weaning weight in the pGLP-2 group catches up with the body weight of normal birth weight piglets. IUGR piglets treated with pGLP-2 microspheres significantly showed increased pancreas weight, serum insulin content, and activities of digestive enzymes (lipase, trypsin, chymotrypsin, and amylase). Injection of pGLP-2 microspheres returned the intestinal absorptive capacity by significantly increasing the mRNA expression of sodium-glucose cotransporter 1 in the jejunum, glucose transporter type 2 in the duodenum and jejunum, H + -coupled transporter, and peptide transporter 1 in the jejunum and ileum. It also returned the redox balance by increasing the catalase mRNA expression and decreasing the heat shock protein 70 mRNA expression. In addition, this improvement was associated with the significant increase in gut diameter, length, and weight induced by pGLP-2. Conclusions Injection of pGLP-2 microspheres was a suitable therapeutic strategy for compensatory growth in low birth weight IUGR piglet.
Coexistence of endometriosis in women with mature cystic ovarian teratoma may not be rare.
Authors: Chae Heesuk 
Published: January 2020

Abstract
Background We investigated the incidence of endometriosis in women with mature cystic ovarian teratoma and analyzed the clinicopathologic features of this occurrence. Methods From January 2017 through December 2018, we retrospectively studied 71 women who had undergone cystectomy for mature cystic ovarian teratoma (n = 55, teratoma group) and coexistence of endometriosis and mature cystic ovarian teratoma (n = 16, complex group). Serum anti-Müllerian hormone (AMH) levels were measured preoperatively and one month after surgery. Results Sixteen (22.54%) patients had coexistence of endometriosis and mature cystic ovarian teratoma (complex group); 55 patients had mature cystic teratoma alone (teratoma group). Early-stage endometriosis (stage I) was present in eight patients and advanced-stage endometriosis (stage III or IV) was present in eight. In five cases (31.25%), the coexistence of endometrioma and mature cystic teratoma in the same ovary was observed. The mean operation time was significantly shorter in the teratoma group than in the complex group (61.02 ± 22.74 vs. 86.31 ± 35.35 min, p = 0.007). The complex group had more dysmenorrhea (43.8% vs. 7.3%, p = 0.002) and a significantly higher rate of decrease in serum anti-Müllerian hormone (AMH) levels (33.06 ± 24.92 vs. 16.31 ± 28.17%, p = 0.048). Conclusion(s) The prevalence of coexisting endometriosis and mature cystic ovarian teratoma may be underestimated. Patients with this rare concurrence may present with worsening dysmenorrhea and damage to ovarian reserve after surgery may be greater in patients with coexisting endometriosis than in patients with mature cystic teratoma alone.
Can SSTR2 expression in previously resected SI-NETs predict overall survival after PRRT treatment of remaining lesions?
Authors: Elf Anna-Karin , Johanson Viktor , Marin Ida , Bergström Anders , Nilsson Ola , Svensson Johanna , Wängberg Bo , Bernhardt Peter , Elias Erik 
Published: January 2020

Abstract
Purpose Small intestinal neuroendocrine tumours (SI-NET) often present with distant metastases at diagnosis. Peptide receptor radiotherapy (PRRT) with radiolabelled somatostatin analogues is a systemic treatment that increases overall survival (OS) in patients with SI-NET. However, PRRT treatment response is variable and predictive factors have not been established. PRRT predominantly targets somatostatin receptor 2 (SSTR2). This study evaluates if SSTR2 expression in SI-NET tumours predicts OS after PRRT treatment.Methods Using a previously constructed Tissue Micro Array (TMA) consisting of 412 SI-NET patients we identified a subgroup consisting of 44 patients (95 tissue samples) that had received PRRT treatment during 2006-2016 at Sahlgrenska University hospital. IHC expression of SSTR2, Ki-67 and neuroendocrine markers were assessed. A retrospective estimation of 177 Lu-DOTATATE uptake in 33 patients was performed. An additional subgroup of 34 patients with paired samples from 3 tumour sites was identified. SSTR2 expression was assessed in corresponding tissue samples (n=102). Data regarding OS and non-surgical treatment were collected for both groups.Results SSTR2 expression did not vary between tumour sites but correlated among the patients’ lesions. Patients were grouped into Low SSTR2 or High SSTR2 depending on levels of SSTR2 expression. OS based on SSTR2 expression was not significantly different. However, PRRT treated patients with low SSTR2 expression received less additional treatment compared to patients with high SSTR2 expression and had a tendency towards higher 177 Lu-DOTATATE uptake.Conclusion The results from the present study suggest that low SSTR2 expression should not exclude patients from PRRT.
Clinical Correlates of Insomnia in Patients with Persistent Post-Traumatic Headache Compared with Migraine
Authors: Kim Soo-Kyoung , Chong Catherine D , Dumkrieger Gina , Ross Katherine , Berisha Visar , Schwedt Todd J. 
Published: January 2020

Abstract
Background: Close associations between insomnia with other clinical factors have been identified in migraine, but there have been few studies investigating associations between insomnia and clinical factors in patients with persistent post-traumatic headache (PPTH). The study objective was to contrast the severity of insomnia symptoms in PPTH, migraine, and healthy controls, and to identify factors associated with insomnia in patients with PPTH vs. migraine.
Methods: In this cross-sectional cohort study, 57 individuals with PPTH attributed to mild traumatic brain injury, 39 with migraine, and 39 healthy controls were included. Participants completed a detailed headache characteristics questionnaire, the Migraine Disability Assessment Scale (MIDAS), Insomnia Severity Index (ISI), Hyperacusis Questionnaire (HQ), Allodynia Symptom Checklist, Photosensitivity Assessment Questionnaire, Beck Depression Inventory (BDI), State-Trait Anxiety Inventory, Post-Traumatic Stress Disorder (PTSD) checklist, Ray Auditory Verbal Learning Test, and the Trail Making Test A and B to assess headache characteristics, disability, insomnia symptoms, sensory hypersensitivities, and neuropsychological factors. Fisher’s test and one-way ANOVA were used to assess group differences of categorical and continuous data. Stepwise logistic regression analyses were conducted to identify clinical variables associated with insomnia symptoms.
Results: Those with PPTH had significantly higher ISI scores (16.72 ± 6.58) compared to migraine patients (11.28 ± 6.42) and healthy controls (4.05 ± 4.80) (p < 0.001). For those with PPTH, insomnia severity was most strongly correlated with the BDI (Spearman's rho (ρ) = 0.634, p < 0.01), followed by Trait Anxiety (ρ = 0.522, p < 0.01), PTSD (ρ = 0.505, p < 0.01), HQ (ρ = 0.469, p < 0.01), State Anxiety (ρ = 0.437, p < 0.01), and MIDAS scores (ρ = 0.364, p < 0.01). According to linear regression models, BDI, headache intensity, and hyperacusis scores were significantly positively associated with insomnia severity in those with PPTH, while only delayed memory recall was negatively associated with insomnia severity in those with migraine.
Conclusions: Insomnia symptoms were more severe in those with PPTH compared to migraine and healthy control cohorts. Depression, headache intensity, and hyperacusis were associated with insomnia in individuals with PPTH. Future studies should determine the bidirectional impact of treating insomnia and its associated symptoms.
A Systematic Approach for Introduction of Novel Treatments to a Chronic Patient Group: sacubitril-valsartan as a case study
Authors: Norberg Helena , Bergdahl Ellinor , Ängerud Karin Hellström , Lindmark Krister 
Published: January 2020

Abstract
Background When novel treatments prove to be better than conventional therapy there is a need for effective introduction, both for cost-effectiveness and to minimize patient suffering. Effective implementation is a challenge in patients with chronic diseases who may be treated both in primary care and/or specialist clinics. Studies have shown that introduction is often unnecessary delayed. Our aims were to develop a model for systematic introduction and to test the feasibility of this model on a new treatment of a chronic disease. We also investigated how such an approach would be received by the patients. Methods The systematic introduction approach is a seven step procedure; Step 1 - define a few main criteria for the specific therapy, Step 2 – primary scan patients with the one or two main criteria using computerised medical records, databases or clinical registries, Step 3 – identify patients applying the other predefined criteria, Step 4 - evaluate if any examinations or laboratory test updates are required, Step 5 - summon identified patients to the clinic with an information letter, Step 6 – discuss treatment with the patient and prescribe to appropriate patients, Step 7 – follow-up on initiated therapy and evaluate the applied process. The model was tested in a case study during introduction of the new drug sacubitril-valsartan in a heart failure population. Patient experiences with the approach were investigated in an interview study with general inductive approach using qualitative content analysis. Results By applying the systematic introduction approach in the case study, 76 out of 1924 patients were identified to be eligible for sacubitril-valsartan and summoned to the clinic to discuss treatment. The content analysis resulted in three final categories of how the model was received by the patients; A good approach , Role of the information letter , and Trust in care . Conclusions The systematic introduction approach ensures that strict criteria are used in the selection process and that a treatment can be implemented in eligible patients within a specified population with limited resources and time. The model was effective in our case study and maintained the patient’s confidence in health care.